Advanced Immunotherapy and Cell Therapy

Advanced Immunotherapy and Cell Therapy (AICT) is a clinical-stage biotechnology company based in Athens, Greece, specializing in the development of personalized cancer immunotherapies. The company focuses on autologous Dendritic Cell (DC) vaccines and adoptive T-cell therapies designed to stimulate a patient's own immune system to recognize and eliminate tumor cells. AICT's lead clinical programs target HER2/neu and PSA-expressing malignancies, with ongoing Phase 2 trials in breast and prostate cancers. The company's proprietary platform involves the ex vivo maturation of dendritic cells and the expansion of tumor-specific T-cells, aiming to provide highly targeted treatments with minimal side effects. AICT works in close collaboration with the Cancer Immunology and Immunotherapy Center (CIIC) to translate innovative immunological research into clinical applications for patients with advanced solid tumors.